

PART I

Statement of Results for the Quarter and Nine Months Ended 31/12/2013

Rupees in Lacs						Sr. No.	Particulars	Rupees in Lacs					
CONSOLIDATED								COMPANY					
3 Months ended 31/12/2013 (Unaudited)	Preceding 3 months ended 30/09/2013 (Unaudited)	Corresponding 3 months ended 31/12/2012 in the previous year (Unaudited)	Year to date figures for the current period ended 31/12/2013 (Unaudited)	Year to date figures for the previous year ended 31/12/2012 (Unaudited)	Previous year ended 31/03/2013 (Audited)			3 Months ended 31/12/2013 (Unaudited)	Preceding 3 months ended 30/09/2013 (Unaudited)	Corresponding 3 months ended 31/12/2012 in the previous year (Unaudited)	Year to date figures for the current period ended 31/12/2013 (Unaudited)	Year to date figures for the previous year ended 31/12/2012 (Unaudited)	Previous year ended 31/03/2013 (Audited)
187,253	173,750	159,420	525,636	468,553	628,484	1	Income from operations	91,369	85,652	74,012	258,255	216,658	297,811
3,449	3,925	3,318	11,262	9,591	12,959	i	Gross Sales	1,656	1,656	1,586	4,844	4,658	6,157
183,804	169,825	156,102	514,374	458,962	615,525	ii	Less: Excise Duty	89,713	83,996	72,426	253,411	212,000	291,654
3,365	4,854	4,309	11,179	15,655	20,252	a	Net Sales	13,035	14,503	13,637	40,646	51,733	75,921
187,169	174,679	160,411	525,553	474,617	635,777	b	Other operating income	102,748	98,499	86,063	294,057	263,733	367,575
41,058	41,255	39,824	120,926	109,824	151,074	c	Total income from operations (net)	26,400	28,877	24,518	80,141	67,859	94,415
31,136	29,612	22,740	81,810	67,681	89,917	2	Expenses	9,853	8,913	7,864	27,686	23,771	33,242
(157)	(3,243)	(5,946)	(9,136)	(7,312)	(8,966)	a	Cost of materials consumed	(814)	(367)	(1,879)	(3,603)	(300)	(905)
26,147	27,297	23,255	79,754	69,245	90,423	b	Purchases of stock-in-trade	12,717	13,085	13,238	39,211	40,521	52,250
4,957	5,176	5,014	14,845	13,777	18,474	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,237	3,247	3,208	9,523	8,782	11,684
59,459	53,704	55,407	168,040	151,249	200,823	d	Employee benefits expense	35,952	30,985	32,149	97,410	87,842	117,943
162,600	153,801	140,294	456,239	404,464	541,745	e	Depreciation and amortisation expense	87,345	84,740	79,098	250,368	228,475	308,629
24,569	20,878	20,117	69,314	70,153	94,032	f	Other expenses	15,403	13,759	6,965	43,689	35,258	58,946
1,278	1,223	1,231	3,754	2,828	3,701	g	Total expenses	6,000	870	1,165	28,824	4,080	5,292
25,847	22,101	21,348	73,068	72,981	97,733	3	Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	21,403	14,629	8,130	72,513	39,338	64,238
1,898	1,933	3,939	6,615	13,708	16,867	4	Other income	780	1,010	2,554	3,250	9,236	11,102
23,949	20,168	17,409	66,453	59,273	80,866	5	Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	20,623	13,619	5,576	69,263	30,102	53,136
347	0	0	347	0	0	6	Finance costs	0	0	0	0	0	0
23,602	20,168	17,409	66,106	59,273	80,866	7	Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	20,623	13,619	5,576	69,263	30,102	53,136
4,083	1,011	6,303	7,125	17,779	11,877	8	Exceptional items	1,130	-1,557	711	572	2,321	3,281
19,519	19,157	11,106	58,981	41,494	68,989	9	Profit/ (Loss) from ordinary activities before tax (7-8)	19,493	15,176	4,865	68,691	27,781	49,855
0	0	0	0	0	0	10	Tax expense	0	0	0	0	0	0
19,519	19,157	11,106	58,981	41,494	68,989	11	Net Profit/ (Loss) from ordinary activities after tax (9-10)	19,493	15,176	4,865	68,691	27,781	49,855
0	0	0	0	0	0	12	Extraordinary items (net of tax expense)	0	0	0	0	0	0
(922)	(820)	(862)	(2,541)	(2,359)	(3,643)	13	Net Profit/ (Loss) for the period (11-12)	19,493	15,176	4,865	68,691	27,781	49,855
18,597	18,337	10,244	56,440	39,135	65,346	14	Share of profit/ (loss) of associates	0	0	0	0	0	0
10,237	10,237	10,237	10,237	10,237	10,237	15	Minority interest	0	0	0	0	0	0
					284,209	16	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	19,493	15,176	4,865	68,691	27,781	49,855
						17	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237	10,237	10,237
						18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						280,912
9.08	8.96	5.00	27.57	19.11	31.92	19 i	Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised):	9.52	7.41	2.38	33.55	13.57	24.35
9.08	8.96	5.00	27.57	19.11	31.92	a	Basic (Rs.)	9.52	7.41	2.38	33.55	13.57	24.35
						b	Diluted (Rs.)	9.52	7.41	2.38	33.55	13.57	24.35
9.08	8.96	5.00	27.57	19.11	31.92	19 ii	Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised):	9.52	7.41	2.38	33.55	13.57	24.35
9.08	8.96	5.00	27.57	19.11	31.92	a	Basic (Rs.)	9.52	7.41	2.38	33.55	13.57	24.35
						b	Diluted (Rs.)	9.52	7.41	2.38	33.55	13.57	24.35

Notes :

- [1] The above results for the quarter/ nine months ended on December 31, 2013 were reviewed by the Audit Committee on February 6, 2014 and then approved by the Board of Directors at their meeting held on February 7, 2014.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Clause 41 of the Listing Agreement.
- [3] The Scheme of Amalgamation of Liva Healthcare Limited, Zydus Animal Health Limited and Zydus Pharmaceuticals Limited with the Company from the appointed date of April 1, 2012, has been sanctioned by the Hon'able High Court of Gujarat. Pursuant to the Scheme becoming effective on August 26, 2013, the figures for the previous quarter/nine months have been recast for the purpose of meaningful comparison with the figures of the current quarter/ nine months.
- [4] The changes in investments during the quarter are as under:
 Liva Pharmaceuticals Limited [initial investments] - Rs. 200 Lacs
 Zydus International Private Limited [additional investments] - Rs. 1,768 Lacs
 Zydus BSV Pharma Private Limited [additional investments] - Rs. 175 Lacs
 Enviro Infrastructure Company Limited [additional investments]- Rs. 90 Lacs
- [5] Consolidated tax expense is net of Alternate Minimum Tax [AMT] Credit amounting to Rs. 2,287 Lacs for the quarter and Rs. 6,755 Lacs for the nine months ended on December 31, 2013, which is recognized as an asset in accordance with guidance note issued by the Institute of Chartered Accountants of India.
- [6] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [7] The Company has one segment of activity viz., "Pharmaceuticals".


PART II

Select information for the Quarter and Nine Months Ended 31/12/2013

3 Months ended 31/12/2013	Preceding 3 months ended 30/09/2013	Corresponding 3 months ended 31/12/2012 in the previous year	Year to date figures for the current period ended 31/12/2013	Year to date figures for the previous year ended 31/12/2012	Previous year ended 31/03/2013	Particulars	3 Months ended 31/12/2013	Preceding 3 months ended 30/09/2013	Corresponding 3 months ended 31/12/2012 in the previous year	Year to date figures for the current period ended 31/12/2013	Year to date figures for the previous year ended 31/12/2012	Previous year ended 31/03/2013
A PARTICULARS OF SHAREHOLDING												
51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	1 Public shareholding	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474
25.21%	25.21%	25.21%	25.21%	25.21%	25.21%	- Number of shares	25.21%	25.21%	25.21%	25.21%	25.21%	25.21%
						- Percentage of Shareholding						
						2 Promoters and Promoter Group Shareholding						
						a Pledged / Encumbered						
Nil	Nil	Nil	Nil	Nil	Nil	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	- Percentage of shares (as a % of the total share capital of the company)	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
						b Non - encumbered						
153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	- Number of shares	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046
100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
74.79%	74.79%	74.79%	74.79%	74.79%	74.79%	- Percentage of shares (as a % of the total share capital of the company)	74.79%	74.79%	74.79%	74.79%	74.79%	74.79%

Particulars	3 months ended 31/12/2013
B INVESTOR COMPLAINTS [In Numbers]	
Pending at the beginning of the quarter	Nil
Received during the quarter	9
Disposed of during the quarter	9
Remaining unresolved at the end of the quarter	Nil

Ahmedabad, February 7, 2014

By Order of the Board,
 For Cadila Healthcare Limited,

 Pankaj R. Patel
 Chairman & Managing Director